ArticleAdvances in therapy2025

Phase I Study to Evaluate the Effect of Hepatic Impairment on Pharmacokinetics and Safety of Tegoprazan, a Potassium Competitive Acid Blocker.

Anhye Kim et al.PubMed ↗Publisher ↗

No numbers read from the abstract.